Impact of age on outcome in patients with advanced ovarian cancer treated within a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR)

2007 ◽  
Vol 2007 ◽  
pp. 77-78
Author(s):  
J.T. Thigpen
Keyword(s):  
Ovarian Cancer ◽  
Advanced Ovarian Cancer ◽  
Phase Iii ◽  
Study Group ◽  
Cancer Study ◽  
Cancer Study Group ◽  
Phase Iii Study

Improving first-line therapy of advanced ovarian cancer – the AGO Ovarian Cancer Study Group perspective

2003 ◽  
Vol 13 (Suppl 2) ◽  
pp. 169-171
Author(s):  
A. Du Bois ◽  
J. Pfisterer ◽  
W. Meier ◽  
U. Wagner
Keyword(s):  
Ovarian Cancer ◽  
Advanced Ovarian Cancer ◽  
Phase Iii ◽  
Ca 125 ◽  
Study Group ◽  
First Line ◽  
Cancer Study ◽  
First Line Therapy ◽  
Line Therapy ◽  
Cancer Study Group

This review displays the AGO Ovarian Cancer Study Group approach towards evaluation of improvement options in first-line therapy of advanced ovarian cancer. Prospectively randomized phase III trials evaluating the addition of newer drugs to standards carboplatin-paclitaxol (TC) as well as pilot trials evaluating new treatment modalities like anti-idiotype CA 125 antibodies or epidermal growth factor receptor (EGFR) modulation are presented.

Sign in / Sign up

Export Citation Format

Share Document